title: Cerebrospinal fluid D-serine and glycine concentrations are unaltered and unaffected by olanzapine therapy in male schizophrenic patients.
abstract: N-Methyl D-aspartate (NMDA)-receptor hypofunction has been implicated in the pathophysiology of schizophrenia and D-serine and glycine add-on therapy to antipsychotics has shown beneficial effects in schizophrenic patients. Nevertheless, previous studies have not shown consistently altered D-serine concentrations in cerebrospinal fluid (CSF) of schizophrenic patients. To confirm and extend these results, CSF concentrations of both endogenous NMDA-receptor co-agonists d-serine and glycine and their common precursor L-serine were analyzed simultaneously in 17 healthy controls and 19 schizophrenic patients before and 6 weeks after daily olanzapine (10 mg) treatment. CSF D-serine, L-serine and glycine concentrations and their relative ratios were similar between schizophrenic patients and controls and no differences were observed before and after olanzapine therapy. Thus, the NMDA-receptor hypofunction hypothesis in schizophrenia is not explained by olanzapine therapy-dependent absolute or relative decreases in CSF D-serine and glycine concentrations in this series of male patients, thereby not providing convenient markers for the disorder.
authors.affiliation: Department of Metabolic and Endocrine Diseases and Department of Biomedical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands. S.Fuchs@umcutrecht.nl
authors.forename: Sabine A
authors.initials: SA
authors.lastname: Fuchs
authors.forename: Martina M J
authors.initials: MM
authors.lastname: De Barse
authors.forename: Floor E
authors.initials: FE
authors.lastname: Scheepers
authors.forename: Wiepke
authors.initials: W
authors.lastname: Cahn
authors.forename: Lambertus
authors.initials: L
authors.lastname: Dorland
authors.forename: Monique G
authors.initials: MG
authors.lastname: de Sain-van der Velden
authors.forename: Leo W J
authors.initials: LW
authors.lastname: Klomp
authors.forename: Ruud
authors.initials: R
authors.lastname: Berger
authors.forename: René S
authors.initials: RS
authors.lastname: Kahn
authors.forename: Tom J
authors.initials: TJ
authors.lastname: de Koning
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use*; D005998:Glycine / Q000134:cerebrospinal fluid*; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D012559:Schizophrenia / Q000134:cerebrospinal fluid* / Q000188:drug therapy*; D012694:Serine / Q000134:cerebrospinal fluid*
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D012694:Serine; D000077152:Olanzapine; D005998:Glycine